Davenport & CO LLC Tempest Therapeutics, Inc. Transaction History
Davenport & CO LLC
- $16.7 Billion
- Q4 2024
A detailed history of Davenport & CO LLC transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 50,000 shares of TPST stock, worth $46,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$46,500
Previous $70,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TPST
# of Institutions
37Shares Held
5.74MCall Options Held
27.9KPut Options Held
139K-
Versant Venture Management, LLC San Francisco, CA3.51MShares$3.26 Million4.35% of portfolio
-
Black Rock Inc. New York, NY550KShares$511,7240.0% of portfolio
-
Jane Street Group, LLC New York, NY493KShares$458,5770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA354KShares$329,4760.0% of portfolio
-
Ubs Group Ag196KShares$181,9780.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $9.69M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...